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Abstract
Background: Rheumatoid arthritis (RA) is a chronic auto-immune disease with extensive articular cartilage
destruction. Aggrecan depletion, mediated by aggrecanases is one of the first signs of early cartilage erosion. We
investigated, whether measurement of aggrecan and fragments thereof in serum, could be used as biomarkers for
joint-disease in RA patients and furthermore characterized the fragments found in the circulation.
Methods: The study consisted of 38 patients, 12 males (62.2 ± 16.0 years) and 26 females (59.8 ± 20.7 years)
diagnosed with RA: 41.5 ± 27.5 mm/h erythrocyte sedimentation rate (ESR), 38.4 ± 34.7 mg/ml C-reactive protein
(CRP) and 4.8 ± 1.7 disease activity score (DAS) and 108 healthy age-matched controls. Aggrecan levels were
measured using two immunoassays, i.e. the 374ARGSVI-G2 sandwich ELISA measuring aggrecanase-mediated
aggrecan degradation and the G1/G2 sandwich assay, detecting aggrecan molecules containing G1 and/or G2
(total aggrecan) We further characterized serum samples by western blots, by using monoclonal antibodies F-78,
binding to G1 and G2, or by BC-3, detecting the aggrecanase-generated N-terminal 374ARGSVI neo-epitope.
Results: Total aggrecan levels in RA patients were significantly decreased from 824.8 ± 31 ng/ml in healthy
controls to 570.5 ± 30 ng/ml (31% decrease, P < 0.0001), as measured by the G1/G2 ELISA. Western blot analysis
with F-78 showed one strong band at 10 kDa, and weaker bands at 25 and 45 kDa in both healthy controls and
RA patients. In contrast, staining for aggrecanase-activity revealed only one strong band in RA patients of 45 kDa.
Conclusion: This is the first study, which characterizes different aggrecan fragments in human serum. The data
strongly suggests that total aggrecan levels, i.e. aggrecan molecules containing G1 and/or G2 are lower in RA
patients, and that RA patients have at least one specific subpopulation of aggrecan fragments, namely aggrecanse
generated 374ARGSVI fragments. Further clinical studies are needed to investigate the potential of G1/G2 as a
structure-related biochemical marker in destructive joint-diseases.
Published: 28 May 2008
BMC Musculoskeletal Disorders 2008, 9:74 doi:10.1186/1471-2474-9-74
Received: 11 February 2008
Accepted: 28 May 2008
This article is available from: http://www.biomedcentral.com/1471-2474/9/74
© 2008 Rousseau et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Musculoskeletal Disorders 2008, 9:74 http://www.biomedcentral.com/1471-2474/9/74
Page 2 of 9
(page number not for citation purposes)
Background
Rheumatoid arthritis (RA) is a chronic auto-inflammatory
disease, which causes functional disability of the joints
[1]. The continuous inflammatory processes lead to exten-
sive remodelling and destruction of the joint-architecture
[1]. The pathology of the disease is characterized by
release of T-cell, macrophage and stromal cell-related
cytokines in the synovial fluid. The local signalling as a
consequence to these inflammatory molecules results in
the expression of an vast array of protease and consequent
degradation of extracellular matrix (ECM) of the articular
cartilage and the adjacent bone [1,2].
Today, medical intervention of RA relies on identifying
drugs targeting joint-pain and swelling caused by the
aforementioned inflammatory processes, as well as halt-
ing radiological progression and damage of the joints [3].
In this matter, one cytokine, which has been given special
focus is tumour necrosis factor alpha (TNFα) [3,4]. The
rationale for developing anti-TNFα treatments in RA is
based on multiple in vitro and in vivo studies, showing the
excessive stimulatory effect of TNFα on a wide range of
biological processes leading to increased inflammation
and tissue destruction [3,4].
The predominant constituents of articular cartilage is col-
lagen type II (60–70% of dry weight) and proteoglycans
(10% of dry weight) of which aggrecan is the main prote-
oglycan. Aggreccan is organized into three globular
domains, G1, G2 and G3. Loss of the inter globular
domain (IGD), which is located between G1 and G2 has
the most deleterious effects to proper tissue-function, due
to loss of the main glycosaminoglycan (GAG) region [5-
8]. The key mediators of cartilage degradation include the
MMPs (Matrix Metallo Proteases) and the closely related
ADAM-TS (a disintegrin and metalloproteinase with
thrombospondin motifs) [10]. The degradation of aggre-
can by MMPs and ADAM-TS, results in among other frag-
ments the 342FFGVG and 374ARGS [10] neo-epitopes, that
may be used to monitor cartilage degradation.
An ex vivo model for investigating the depletion of the
ECM components is the cartilage explant model. Cartilage
explants provide a robust system with a high in vivo-like-
ness where the chondrocytes are anchored in the natural
ECM [9,10]. Articular cartilage explants subjected to pro-
inflammatory cytokines provide a biologically relevant
model to study the time-dependent release of ECM degra-
dation-fragments [10-12].
Until now, the gold standard for clinically diagnosing RA
patients has been based on self-reported symptoms,
assessment of swollen and tender joints, quantification of
levels of rheumatoid factor, anti-CCP auto-antibodies
against citrullinated filaggrin peptides, as well as imaging
techniques, such as X-ray of the joints. Unfortunately, the
use of radiological-methods is not without limitations, as
significant joint-damage has taken place, by the time,
signs of joint-destruction are detected by X-ray [13,14].
Furthermore, radiological imaging of the joints is a cum-
bersome procedure, where long follow-up periods are
necessary in order to assess noticeable changes of the artic-
ular cartilage [15]. Markers like C-reactive protein (CRP),
matrix metalloproteinase-3 (MMP-3) and YKL-40 have
also been used for assessing the extent of synovitis in RA
patients [16-19]. But CRP and MMP-3 are not specific to
the synovial tissue [20], and though serum YKL-40 levels
are elevated in RA individuals, this marker is highly corre-
lated to CRP levels, and therefore may not be of further
value to reflect joint-destruction [21]. Consequently,
more dynamic sensitive non-invasive markers are desired,
which may aid in providing information of the structural
damage of the joints and the efficacy of structure-modify-
ing drugs.
In the current study, we have used corresponding immu-
noassays to investigate, if monitoring of aggrecan, or its
fragments in the circulation, can be used as valid biomar-
kers for assessing joint-damage in RA patients, and more-
over, characterized the fragments found in human serum.
Methods
Study participants
The clinical data were evaluated by selecting 38 patients,
12 males (62.2 ± 16.0 years), (83.0 ± 13.9 kg), (173.0 ±
6.4 cm) and 26 females (59.8 ± 20.7 years), (164.2 ± 5.8
cm) (64.8 ± 10.9 kg) (mean ± SD) with RA. The eryhthro-
cyte sedimentation rate (ESR), C-reactive protein (CRP)
and disease activity score (DAS)(37) were 41.5 ± 27.5
mm/h, 38.4 ± 34.7 mg/l and 4.8 ± 1.7 respectively. X-ray
pictures were evaluated according to the Steinbrocker
method [22] and scored 1–4, which was 2 ± 0.9. Either,
the patients were untreated, or underwent drug-treatment
with different dosages of 1) disease modifying anti-rheu-
matic drugs (DMARDs): Prednisolone, Sulfasalazin,
Methotrexate, Leflunomid, Azathioprin either alone, or in
combination (39.5% of the patients were on co-medica-
tions), or 2) with non-steroidal anti-rheumatic drugs:
Rofecoxib, Diclofenac, Valdecoxib, Acemetacin, Piroxi-
cam, Celecoxib, Ibuprofen alone. The majority of the
patients were positive for rheumatoid factors and typical
rheumatoid nodes. A set of 108 healthy age-matched
males and females were used as controls for the RA
patients (60.6 ± 13.9 years). The study was approved by
the Ethical Committee of Medical Faculty at Friedrich-
Schiller University (Jena, Germany-reference number
1019-01/03) and written patient consent was received for
the study. Blood was collected from fasting individuals in
the morning, and allowed to clot at room temperature for
at least 10 minutes. Then the collected blood was centri-BMC Musculoskeletal Disorders 2008, 9:74 http://www.biomedcentral.com/1471-2474/9/74
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fuged for 10 minutes at 1000 g and serum was harvested,
and stored at -70°C, before analysis. For Western Blot
analysis, 2 groups of patients were randomly selected: 15
plasma samples from RA patients (61 ± 3.6 years, DAS >5)
and 22 healthy age-matched (62 ± 2.7 years) controls.
Reagents
ADAMTS-4 (Cat. Number CC1028) 5 μg/25 μl and poly-
clonal rabbit antimouse antibody (Cat. Number AQ160)
1 mg/ml were from Chemicon, USA. Tumour Necrosis
Factor alpha (TNFα) 10 μg/ml (Cat. Number 210-TA) was
bought from R & D systems. Maxisorp-plates were pur-
chased from Nunc. (Cat. Number 439454), while strepta-
vidin-coated plates were bought from Roche (Cat.
Number 1207733). Purified bovine aggrecan 1 mg (Cat.
Number A-1960), Oncostatin M 10 μg (OSM) (Cat.
Number O 9635-10UG), Peroxidase-conjugated rabbit
anti-mouse secondary antibody (Fc specific) (A-2554)
were all purchased from Sigma Aldrich, DK, and Liquid II
was purchased from Roche. The ELISA assay quantifying
the levels of auto-antibodies against citrullinated filaggrin
peptides, Diastat Anti-CCP (Cat. Number UK-FCCP200),
was purchased from Axis-Shield Diagnostics, UK. Nitro-
cellulose membrane (Cat. Number FB 0303-1) was
bought from Whatman Schleicher and Schuell. Normal
freeze-dried mouse serum (Cat. Number NS03L) was
bought from Calbiochem. Cell supernatants of the mon-
oclonal antibody BC-3 (Cat. Number ab 3773) against the
aggrecanase-generated neo-epitope 374ARGSVI was pur-
chased from Abcam. The culture medium for the human
articular cartilage explants were Dulbecco's Modified
Eagle Medium (D-MEM) and Ham F12 from Life Technol-
ogies, US. Penicillin and streptomycin 10000 μg/ml (Cat.
number DE 17-602E) was from Invitrogen, DK. The ECL
detection system for western blot (Cat. Number RPN
2109) was from Amersham.
Human articular cartilage
Human articular cartilage was obtained from the ortho-
paedic surgery unit during knee arthroplasty of both
females and males with late-stage OA or RA (Farsoe Nor-
djylland, Denmark). The articular cartilage was isolated
without the adhering subchondral bone. The study was
conducted according to the ethical committee approval
number VN-2060031. RA and OA knee cartilage in
response to the cytokines displayed smilar inductions pat-
terns.
Pieces of cartilage (20–25 mg) were placed in 96 well
plates in 4-replicates and incubated for 21 days at 37°C
with 5% CO2 in serum-free D-MEM medium. Explants
were incubated either non-stimulated, or with 10 ng/ml
oncostatin M (OSM) in combination with 20 ng/ml
tumour necrosis factor alpha (TNFα) [10,23-25] to stimu-
late cartilage degradation. As negative control, cartilage
was placed in cryo-tubes, frozen in liquid N2, and thawed
at 37°C in water-bath for three repeated freeze-thaw
cycles. The explant culture medium was replaced every 3rd
day for 21 days. The conditioned medium was stored at -
20°C until analysis.
Detection of aggrecan neo-epitopes
Aggrecanase -mediated aggrecan degradation was quanti-
fied using the 374ARGSVI-G2 ELISA [26]. Briefly, it is a
sandwich assay using monoclonal antibody BC-3, recog-
nizing the aggrecanase generated neo-epitope 374ARGSVI,
as catching antibody, and POD-labelled monoclonal anti-
body F-78 binding to the G2 domain as detector antibody
[12]. Briefly, microtitre plates are coated overnight with
anti-mouse immunoglobulins (rabbit) diluted in Na2CO3
buffer, washed, incubated with monoclonal antibody BC-
3 diluted PBS-BTB (1 hr, 20°C), washed again and then
incubated with sample diluted in PBS-BTB (1 hr, 20°C).
Purified bovine aggrecan treated with ADAM-TS4 was
used as calibrators. After washing, POD-labelled F78
diluted in PBS-BTB was added to each well (1 hr, 20°C),
washed and then incubated with TMB. After 15 minutes
the reaction is stopped with 0.18 M H2SO4. The intra and
interassay variation of the assay was 9.6% and 11.2%,
respectively.
Detection of aggrecan turnover
The level of released total aggrecan molecules were quan-
tified using the G1/G2 assay. This assay employs F-78
both as the catching and detecting antibody, binding to a
repetitive epitope exposed at least twice on G1 and G2,
and detects intact G1-G2, or free catabolized G1 or G2
domains [12]. Briefly, microtitre plates precoated with
streptavidin are incubated with biotinylated F78 diluted
PBS-BTB (1 hr, 20°C), washed again and then incubated
with sample diluted in PBS-BTB (1 hr, 20°C). Purified
bovine aggrecan was used as calibrators. After washing,
POD-labelled F78 diluted in PBS-BTB was added to each
well (1 hr, 20°C), washed and then incubated with TMB.
After 15 minutes the reaction is stopped with 0.18 M
H2SO4. Testing human serum samples, the G1/G2 ELISA
was modified by addition of a HAMA blocking agent, i.e
10% Liquid II, to the buffer used for dilution of sample
and detecting antibody. The intra and interassay of the
assay was 7.1% and 8.9%, respectively [12]. Dilution
recovery was 110.4% (103.9–116.9%) (mean (range)),
and spiking recovery was 98.9% (88.9–110.3%).
Detection of anti-CCP
Anti-CCP-ELISA was used according to the procedure
described by the manufacturer (Axis-Shield Diagnostics,
UK). Precision data of intra and interassay of the assay is
between 4.7–7.2% [27].BMC Musculoskeletal Disorders 2008, 9:74 http://www.biomedcentral.com/1471-2474/9/74
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Western blotting
A pool of 15 plasma samples from RA patients, or 22 sam-
ples from healthy controls were diluted 10 times with
milli-Q water and boiled for 5 minutes and 30 microliter
was run in 4–20% pre-casted gels (Bio-Rad) under reduc-
ing conditions (migration buffer: Tris 25 mM, Glycine
200 mM, Sodium Dodecyl Sulfate (SDS) 3.5 mM, pH =
8.3). After transferring the proteins to a polyvinyldifluo-
ride (PVDF) membrane overnight at 50 V in a 10 mM
CAPS buffer with 5% methanol, the membrane was
blocked with 5% non-fat milk in PBS buffer (1.5 mM
KH2PO4, 8 mM Na2HPO42H2O, 2.7 mM KCl, 150 mM
NaCl with 0.05% Tween-20) with shaking for 1 hour at
room temperature (RT). After washing, the following anti-
bodies were applied in appropriate dilutions in PBS buffer
with 2.5% bovine serum albumin and 0.05% Tween-20
for 4 hours at RT, or overnight (ON) at 4°C: BC-3 cell-
supernatants diluted 1:100, or F-78-POD at a final con-
centration of 2 μg/ml respectively. For testing the specifi-
city of the obtained bands, inhibition tests were
performed with the appropriate antigens. For the antigen-
blocking tests, the used concentrations were: intact bovine
aggrecan at 333 μg/ml and 374ARGSVI-peptide at 200 μg/
ml. After washing, the membranes were incubated for 1
hour at RT with a peroxidase (POD)-labeled rabbit anti-
mouse antibody for BC-3 1:30000, or directly detected for
the POD-coupled F-78. The results were visualized using
an ECL system.
Statistics
Results are shown as mean + standard error of mean
(SEM). Differences between mean values were compared
by the non-parametric two-tailed student's t-test using the
GraphPad Prism software. Differences were considered
statistical significant, if P < 0.05.
Results
Increased release of aggrecan and its fragments after 
catabolic stimulation of human cartilage explants with 
pro-inflammatory cytokines
First, the local response of human chondrocytes subjected
to catabolic stimuli by exposure to pro-inflammatory
cytokines was investigated. For this purpose, OSM was
used in combination with TNFα, and the level of aggrecan
and its fragments released into the conditioned medium
was evaluated by corresponding immuno-assays.
While release of aggrecanase-generated 374ARGSVI-G2
fragments were elevated at all time-points in the study-
period in response to catabolic stimulation (Figure 1a),
the release of G1/G2 could not be detected at late stages in
the supernatant (Figure 2a).
The accumulated release of the markers at the end of the
study-period resulted in a release of 374ARGSVI-G2 and
G1/G2, elevated approximately 915% (from 5.15 to
52.27  μg/ml/mg cartilage) and 214% (from 47.83 to
150.19  μg/ml/mg cartilage) respectively compared to
vehicle (Figure 1b, 2b).
Patients with Rheumatoid Arthritis have an altered 
aggrecan profile compared to healthy controls
To further investigate the aggrecan degradation profile in
vivo under pathologically relevant conditions, we investi-
gated the systemic levels of total G1/G2 aggrecan mole-
Measurement of aggrecanase-generated 374ARGSVI-G2 frag- ments in human OA patient Figure 1
Measurement of aggrecanase-generated 374ARGSVI-
G2 fragments in human OA patient. Human cartilage 
explants were cultured for 21 days either non-stimulated (-t-
), or treated with pro-inflammatory cytokines 10 ng/ml 
oncostatin M (OSM) in combination with 20 ng/ml tumour 
necrosis factor alpha (TNFα) (--). The conditioned medium 
from four independent wells was measured for the presence 
of aggrecanase-generated 374ARGSVI-G2 fragments at each 
collected time-point (a), or (b) accumulated throughout the 
study-period. As negative control, explants were frozen and 
thawed four times in liquid nitrogen (--). The asterisks indi-
cate significant differences (P < 0.05). For the statistical analy-
sis, two-tailed non-parametric t tests were used.BMC Musculoskeletal Disorders 2008, 9:74 http://www.biomedcentral.com/1471-2474/9/74
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cules in patients diagnosed with RA in order to test the
clinical applicability of the assay. For this purpose, a
cohort, consisting of 38 patients with RA and 108 healthy
age-matched controls was used. Similarly, G1/G2 was
compared to the well-recognised RA marker anti-CCP,
which is specific for auto-antibodies against citrullinated
filaggrin peptides, however not related directly to articular
cartilage damage.
The levels of anti-CCP were increased in RA patients (7.00
± 4.14 U/ml (mean ± SEM) compared to controls (0.69 ±
0.06 U/ml U/ml) (P < 0.0001) (Figure 3), i.e. approxi-
mately 10 times elevated. On the other hand, the aggrecan
turnover was significantly suppressed from 824.8 ng/ml
in healthy controls to 570.5 ng/ml, corresponding to a
decrease of 31% (P < 0.0001) (Figure 4). In this popula-
tion of patients with RA, G1/G2 was not correlated to nei-
ther ESR, CRP, nor disease activity score.
Detection of aggrecan fragments in human serum by 
western blot analysis
The different analytes found in the circulation of aggrecan
were characterized by western blotting, where staining
was either with F-78, binding to G1 and/or G2 containing
molecules, or BC-3, detecting the aggrecanase-generated
374ARGSVI N-terminal flanking fragments.
Western blot analysis showed one strong band detected at
10 kDa, and weaker bands at 25 and 45 kDa in both
healthy controls and RA patients with F-78 staining (Fig-
ure 5a). On the other hand, only one strong aggrecanase-
generated 374ARGSVI band was present in RA patients of
45 kDa when staining was done with BC-3 (Figure 5b).
The binding of both antibodies to the immobilized aggre-
can fragments on the membrane was completely inhib-
ited by incubation with the homologous peptides (Data
not shown).
Discussion
Biochemical markers offer the advantage to monitor joint-
destruction more dynamically than traditional radio-
graphic techniques, and may therefore allow medical
intervention prior to extensive damage of the joints has
taken place. Presently, no structure-related markers of
Measurement of total aggrecan turnover, G1/G2, in human  OA patient Figure 2
Measurement of total aggrecan turnover, G1/G2, in 
human OA patient. Human cartilage explants were cul-
tured for 21 days either non-stimulated (-t-), or treated with 
pro-inflammatory cytokines 10 ng/ml oncostatin M (OSM) in 
combination with 20 ng/ml tumour necrosis factor alpha 
(TNFα) (--). The conditioned medium from four independ-
ent wells was measured for the presence of G1/G2 mole-
cules at each collected time-point (a), or (b) accumulated 
throughout the study-period. As negative control, explants 
were frozen and thawed four times in liquid nitrogen (--). 
The asterisks indicate significant differences (P < 0.05). For 
the statistical analysis, two-tailed non-parametric t tests were 
used.
Quantification of anti-CCP in RA patients Figure 3
Quantification of anti-CCP in RA patients. Serum sam-
ples from healthy individuals (N = 104) and patients with 
Rheumatoid arthritis (RA) (N = 38) were analyzed for their 
anti-CCP level. The activities are log-transformed data and 
the values are mean + SEM. The asterisks indicate significant 
differences (P < 0.05). For the statistical analysis, two-tailed 
non-parametric t-tests were used.BMC Musculoskeletal Disorders 2008, 9:74 http://www.biomedcentral.com/1471-2474/9/74
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articular cartilage proteoglycans have been detected in
serum. The primary aim of the current study was to inves-
tigate the aggrecan turnover and profilein RA patients
receiving treatment. In the present study, we clearly dem-
onstrated that RA patients have significant decrease in cir-
culating levels of aggrecan core-protein containing the G1
and/or G2 domain, and that RA patients have an specific
subpopulation aggrecanase degraded aggrecan fragments.
In RA patients, elevated anti-CCP levels were detected,
which was expected due to increased inflammation in
arthritic individuals (Figure 3). In contrast, the aggrecan
turnover was significantly decreased in RA patients com-
pared to controls (Figure 4). Although this effect biologi-
cally may be interpreted as extensive loss of articular
cartilage, the potential effect drug-treatments cannot be
ruled out. The current data needs to be validated in longi-
tudinal studies, to investigate the time dependent release
of these aggrecan molecules. In alignment, the clinical
potential of the G1/G2 assay to predict structure modify-
ing effects of novel treatments would be of high interest.
At present, the sensitivity of the 374ARGSVI -G2 ELISA
Quantification of total aggrecan turnover, G1/G2, in RA  patients Figure 4
Quantification of total aggrecan turnover, G1/G2, in 
RA patients. Serum samples from healthy individuals (N = 
108) and patients with Rheumatoid arthritis (RA) (N = 38) 
were analyzed in the G1/G2 assay. The concentrations are 
log-transformed data and the values are mean + SEM. The 
asterisks indicate significant differences (P < 0.05). For the 
statistical analysis, two-tailed non-parametric t-tests were 
used.
Characterization of aggrecan fragments in RA patients by western blot analysis Figure 5
Characterization of aggrecan fragments in RA patients by western blot analysis. Western blot analysis was done 
using 15 independent human plasma samples pooled from patients with Rheumatoid arthritis (RA) (lane 3) and the membrane 
was stained with (a) the monoclonal antibody F-78 raised against intact bovine aggrecan, binding to G1 and G2, or with (b) 
BC-3 raised against the aggrecanase-generated 374ARGSVI sequence. As control, plasma samples from 22 healthy individuals 
were used (lane 2). A standard molecular weight marker was also run to determine the size of the detected fragments (lane 1).BMC Musculoskeletal Disorders 2008, 9:74 http://www.biomedcentral.com/1471-2474/9/74
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does not allow reliable measurements in human serum to
be performed.
When investigating the characteristics of analytes in
human serum by western blot analysis, one specific aggre-
canase-generated  374ARGSVI band of approximately 45
kDa was observed only present in RA serum (Figure 5b).
This is in agreement with the general idea that there is an
elevated inflammation in the joints of RA individuals due
to recruitment of various inflammatory cells that secrete
excessive levels of cytokines and growth factors [28,29].
This leads to the expression of a range of proteases of
which the ADAM-TS have been show to be the main medi-
ators of aggrecan destruction, that results in the genera-
tion and release of the specific fragment of aggercan,
374ARGSVI [10]. The band could potentially represent an
aggrecan fragment with the 374ARGSVI neo-epitope at the
N-terminal further comprising the G2 domain at the C-
terminal. This would be in alignment with the observa-
tion that 374ARGSVI-G2 fragments were detected in cata-
bolically stimulated ex vivo explant cultures (Figure 1a,b).
This fragments may not be connected with the CS1 and
CS2 glycosaminoglycan regions, as in this case, they
would be expected to give rise to high molecular-weight
bands. This is in alignment with that extensive protease
activities processes aggercan to smaller fragments.
Though, aggrecan fragments found in the circulation had
never been characterized prior to this study, different
investigators have analyzed the characteristics of mole-
cules found in OA synovial fluid [30-32]. The N-termi-
nally flanked 374ARGSVI neo-epitope was detected in a
heterogenous population of fragments in all the above-
mentioned studies. The molecular weights detected
respectively in these studies were in the range of 90–150
[30], 250 kDa [31] and 129–311 kDa [32]. Struglics and
investigators observed that 374ARGSVI was linked to the
CS-1, but our detection of a band of 45 kDa further sug-
gests a cleavage in the C-terminal part of 374ARGSVI-gen-
erated fragments in the synovium before reaching the
circulation, which could likely be at the CFRG656-657ISAV
MMP-site [32]. However, identical bands of 10, 25 and 45
kDa were observed in both healthy controls, as well as RA
patients after staining with F-78 (Figure 5a), different
from the G1/G2 ELISA results (Figure 4), indicating that
these fragments are a part of normal aggrecan turnover,
and therefore, do not reflect a pathological turnover-proc-
ess. Future efforts of affinity-column-purification of these
fragments with F-78 and BC-3 from RA serum, followed
by gel-electrophoresis, western blotting and sequencing of
the bands may aid in understanding of the molecular
mechanisms of normal and pathological aggrecan turno-
ver in joint-debilitating diseases.
To further characterize the aggrecan turnover profile, we
used explants from human articular cartilage, and investi-
gated the release of G1/G2, or aggrecanase generated frag-
ment  374ARGSVI-G2 aggrecan molecules locally after
catabolic treatment. We observed release of 374ARGSVI-G2
fragments starting from the initial phases and throughout
the whole study-period (Figure 1a), generally demonstrat-
ing aggrecanase-activity only at initial time-points [33-
36]. The observed differences may be caused by the fact
that human articular cartilage from a late-stage OA indi-
vidual was used in this study, presumably with a high
background protease-activity in the matrix, due to the
advanced disease stage.
The lack of elevated levels of G1/G2 analytes observed
after catabolic treatment of explants at late stages com-
pared to vehicle (Figure 2a) was somehow reflected in the
circulation, as the concentrations in RA patients was sig-
nificantly decreased compared to controls (Figure 4). Col-
lectively, the decrease of aggrecan levels in the RA patients
compared to healthy individuals might be a result of the
disease being at a progressed stage, where much of the car-
tilage had already been lost.
There are important limitations associated with current
study. Firstly the relative small sample size analysed, and
importantly the lack of longitudinal analysis. The current
data needs to be validated in longitudinal studies, to
investigate the time dependent release of these aggrecan
molecules and aggrecan profiles. In addition, preferably
in clinical trials, there are a need to investigate the clinical
potential of the G1/G2 assay to predict structure changes,
and whether the assay might be used as a prognostic
marker for progression in both the absence and presence
of treatment.
Conclusion
For the first time, we demonstrate that the aggrecan turn-
over is significantly decreased in serum of RA patients.
Future clinical intervention studies with chondro-protec-
tive agents are needed to evaluate its potential as a struc-
ture-related marker in destructive joint-diseases.
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